Camille Bedrosian Sells 12,039 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Camille Bedrosian sold 12,039 shares of the company’s stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $14.58, for a total value of $175,528.62. Following the completion of the sale, the insider owned 182,336 shares in the company, valued at $2,658,458.88. This represents a 6.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Amylyx Pharmaceuticals Stock Up 1.0%

NASDAQ:AMLX opened at $13.42 on Friday. The stock’s 50 day moving average price is $10.29 and its two-hundred day moving average price is $7.00. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -5.37 and a beta of -0.33. Amylyx Pharmaceuticals, Inc. has a 12-month low of $2.60 and a 12-month high of $15.15.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.02). Equities research analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 EPS for the current year.

Wall Street Analyst Weigh In

AMLX has been the subject of several recent research reports. Bank of America boosted their price target on Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Friday. The Goldman Sachs Group upped their price objective on Amylyx Pharmaceuticals from $10.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, September 16th. Citigroup started coverage on Amylyx Pharmaceuticals in a report on Tuesday, June 17th. They issued a “buy” rating and a $12.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Amylyx Pharmaceuticals in a report on Saturday, September 27th. Finally, Guggenheim upped their price objective on Amylyx Pharmaceuticals from $17.00 to $25.00 and gave the company a “buy” rating in a report on Monday, September 15th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Amylyx Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.75.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. lifted its holdings in Amylyx Pharmaceuticals by 18.3% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 17,188 shares of the company’s stock worth $61,000 after buying an additional 2,653 shares during the period. Hsbc Holdings PLC lifted its holdings in Amylyx Pharmaceuticals by 24.7% during the 1st quarter. Hsbc Holdings PLC now owns 14,419 shares of the company’s stock worth $51,000 after buying an additional 2,853 shares during the period. California State Teachers Retirement System acquired a new position in Amylyx Pharmaceuticals during the 2nd quarter worth about $28,000. BNP Paribas Financial Markets lifted its holdings in Amylyx Pharmaceuticals by 433.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock worth $47,000 after buying an additional 5,904 shares during the period. Finally, R Squared Ltd lifted its holdings in Amylyx Pharmaceuticals by 99.9% during the 1st quarter. R Squared Ltd now owns 12,736 shares of the company’s stock worth $45,000 after buying an additional 6,366 shares during the period. Institutional investors own 95.84% of the company’s stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.